TOGETHER-PsA: tirzepatide plus ixekizumab

A Phase 3b trial called TOGETHER-PsA has tested what happens when you add tirzepatide to ixekizumab in adults with active psoriatic arthritis (PsA) and overweight or obesity. The combination outperformed ixekizumab alone on joint disease control, weight reduction, and patient-reported function^[1]. A commentary published days later in the same journal argues that this result points toward a broader shift: treating PsA by metabolic phenotype, not just joint inflammation^[2].

What TOGETHER-PsA tested

The trial enrolled 271 adults with active PsA and either obesity (BMI 30 or above) or overweight (BMI 27 to 29.9) with at least one weight-related comorbidity. Participants were randomised to ixekizumab plus tirzepatide (n=138) or ixekizumab alone (n=133) for 52 weeks. Ixekizumab is an IL-17A inhibitor already approved for PsA; tirzepatide is a dual GIP/GLP-1 receptor agonist approved for type-2 diabetes and obesity^[1].

The primary endpoint was a composite: simultaneous achievement of ACR50 (50% improvement in American College of Rheumatology criteria) and at least 10% body-weight reduction at 36 weeks. That composite was chosen deliberately. It forced the trial to measure joint disease and metabolic improvement together, rather than treating them as separate problems^[1].

The numbers

The combination group hit the composite primary endpoint at 31.7%, versus 0.8% for ixekizumab alone (P < 0.001). On ACR50 alone, the combination reached 33.5% versus 20.4% (P = 0.02), with separation visible by week 4. ACR20 response, minimal disease activity, and Psoriasis Area and Severity Index scores all favoured the combination arm^[1].

Patient-reported outcomes followed the same pattern. Physical function measured by the Health Assessment Questionnaire improved by an additional 0.2 points in the combination group (P < 0.001), and fatigue scores improved by 3.8 points on the FACIT-Fatigue scale (P < 0.01). Safety profiles were consistent with what is already known for each drug individually^[1].

Why the commentary calls for precision phenotyping

Caso and colleagues, writing in Arthritis & Rheumatology, argue that TOGETHER-PsA is not just a combination-therapy trial. They see it as evidence that PsA patients with metabolic comorbidities represent a distinct phenotype that responds differently to treatment^[2]. The idea is that obesity in PsA is not simply a comorbidity sitting alongside joint disease. It actively drives inflammation through shared metabolic pathways.

This framing has support in the body-composition literature. A 2021 cross-sectional study by Ferguson and colleagues found that PsA patients carry significantly more visceral adipose tissue than matched controls, with predicted propensity for coronary heart disease 1.27 times higher and type-2 diabetes 1.83 times higher^[3]. Overweight or obesity is reported in 72% to 82% of people with PsA^[1]. Those numbers suggest that the metabolic phenotype is the norm, not the exception.

A 2026 review in Frontiers in Immunology examined the broader evidence for GLP-1 receptor agonists in psoriatic disease. The authors found that liraglutide and semaglutide improve psoriasis severity, metabolic parameters, and inflammatory markers through mechanisms that go beyond weight loss alone, suggesting direct immunomodulatory effects^[4]. Two open-label PsA trials (TOGETHER-PsA and TOGETHER AMPLIFY-PsA) showed improvements in disease activity alongside metabolic benefits.

What this does not tell us

The trial was 52 weeks long and enrolled 271 people. That is large enough to detect a signal on the composite endpoint but not large enough to characterise rare adverse events or long-term durability. Whether the ACR50 advantage holds at two or three years is an open question. The trial also tested only one combination (ixekizumab plus tirzepatide), so it is not clear whether other biologics paired with a GIP/GLP-1 agonist would produce similar results.

The precision-phenotyping argument in the commentary is a hypothesis, not a validated clinical framework. There is no consensus definition of a "metabolic PsA phenotype," no validated biomarker panel to identify it, and no treatment algorithm that routes patients into phenotype-specific arms. The commentary itself acknowledges this. For context on how tirzepatide works at the receptor level, see the mechanism section on the tirzepatide overview page.

What to watch next

TOGETHER AMPLIFY-PsA, a second open-label trial assessing ixekizumab with and without tirzepatide, is ongoing. Longer follow-up data from TOGETHER-PsA will clarify whether the combination advantage is durable. And the broader question, whether GLP-1 class drugs have direct anti-inflammatory effects in autoimmune joint disease beyond their metabolic benefits, is the subject of active research^[4].

For more on tirzepatide's mechanism and approved indications, see the tirzepatide overview. For semaglutide's role in the GLP-1 class, see the semaglutide overview.

If you have psoriatic arthritis and are considering any change to your treatment, consult your rheumatologist. This article is for informational purposes only and does not constitute medical advice.